

# Nimish Vakil

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4198989/nimish-vakil-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141  
papers

11,435  
citations

44  
h-index

106  
g-index

155  
ext. papers

12,873  
ext. citations

5.2  
avg, IF

6.17  
L-index

#	Paper	IF	Citations
141	Colorectal cancer in 18- to 49-year-olds: rising rates, presentation, and outcome in a large integrated health system. <i>Gastrointestinal Endoscopy</i> , <b>2021</b> , 94, 618-626	5.2	3
140	IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. <i>Gastroenterology</i> , <b>2020</b> , 158, 2093-2103	13.3	20
139	Commentary: tegaserod and IBS, two decades on. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 200-201	6.1	
138	Multitarget stool DNA testing for the prevention of colon cancer: outcomes in a large integrated healthcare system. <i>Gastrointestinal Endoscopy</i> , <b>2020</b> , 92, 334-341	5.2	4
137	Microbiome: In Search of Mechanistic Information and Relevance. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1014-1016	0.7	3
136	Rifabutin Triple Therapy is Effective in Patients With Multidrug-resistant Strains of <i>Helicobacter pylori</i> . <i>Journal of Clinical Gastroenterology</i> , <b>2018</b> , 52, 137-140	3	22
135	Dietary Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAPs) and Gastrointestinal Disease. <i>Nutrition in Clinical Practice</i> , <b>2018</b> , 33, 468-475	3.6	10
134	ACG and CAG Clinical Guideline: Management of Dyspepsia. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 988-1013	0.7	259
133	Diagnosis of gastro-oesophageal reflux disease is enhanced by adding oesophageal histology and excluding epigastric pain. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1350-1357	6.1	10
132	Glucagon Is a Safe and Inexpensive Initial Strategy in Esophageal Food Bolus Impaction. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 841-5	4	15
131	Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. <i>United European Gastroenterology Journal</i> , <b>2016</b> , 4, 413-22	5.3	26
130	Mortality and complications following surgery for diverticulitis: Systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , <b>2016</b> , 4, 706-713	5.3	22
129	Epithelial Thickness is a Marker of Gastroesophageal Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1544-1551.e1	6.9	28
128	Sleep disturbance due to heartburn and regurgitation is common in patients with functional dyspepsia. <i>United European Gastroenterology Journal</i> , <b>2016</b> , 4, 191-8	5.3	13
127	Rationale for a <i>Helicobacter pylori</i> Test and Treatment Strategy in Gastroesophageal Reflux Disease. <i>Gastroenterology Clinics of North America</i> , <b>2015</b> , 44, 661-6	4.4	1
126	BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 662-82; quiz 683	0.7	92
125	Gender differences in symptoms in partial responders to proton pump inhibitors for gastro-oesophageal reflux disease. <i>United European Gastroenterology Journal</i> , <b>2015</b> , 3, 443-52	5.3	3

124	Salivary pepsin to diagnose GORD?. <i>Gut</i> , <b>2015</b> , 64, 361-2	19.2	7
123	Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal reflux disease: a post hoc analysis of two study populations. <i>BMC Gastroenterology</i> , <b>2014</b> , 14, 177	3	3
122	Prevalence of gastro-oesophageal reflux disease with upper gastrointestinal symptoms without heartburn and regurgitation. <i>United European Gastroenterology Journal</i> , <b>2014</b> , 2, 173-8	5.3	5
121	The initial diagnosis of GERD. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2013</b> , 27, 365-71	2.5	10
120	Culture-based selection therapy for patients who did not respond to previous treatment for <i>Helicobacter pylori</i> infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 507-10	6.9	43
119	Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 767-74	0.7	53
118	Global eradication rates for <i>Helicobacter pylori</i> infection: systematic review and meta-analysis of sequential therapy. <i>BMJ, The</i> , <b>2013</b> , 347, f4587	5.9	178
117	Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitors. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 1018-26	2.4	5
116	Response to Tack and Carbone. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1810	0.7	
115	Treatment for <i>H. pylori</i> infection: new challenges with antimicrobial resistance. <i>Journal of Clinical Gastroenterology</i> , <b>2013</b> , 47, 383-8	3	37
114	Commentary: balloon distension of the oesophagus - not ready for primetime. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 202-3	6.1	
113	Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 1360-6	6.9	76
112	Prescribing proton pump inhibitors: is it time to pause and rethink?. <i>Drugs</i> , <b>2012</b> , 72, 437-45	12.1	39
111	Funding source and conflict of interest disclosures by authors and editors in gastroenterology specialty journals revisited. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 690-5	6.1	10
110	Validation of the reflux symptom questionnaire electronic diary in partial responders to proton pump inhibitor therapy. <i>Clinical and Translational Gastroenterology</i> , <b>2012</b> , 3, e7	4.2	15
109	Expandable metal stents: principles and tissue responses. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2011</b> , 21, 351-7, vii	3.3	6
108	Aerobic exercise and caloric reduction should be the key lifestyle modifications in obese patients with GERD. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 1133-4; discussion 1134-5	6.1	2
107	Empiric quadruple vs. triple therapy for primary treatment of <i>Helicobacter pylori</i> infection: Systematic review and meta-analysis of efficacy and tolerability. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 65-73	0.7	149

106	Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. <i>Gut</i> , <b>2010</b> , 59, 714-21	19.2	210
105	GastroÖophageale Refluxkrankheit. <i>Monatsschrift Fur Kinderheilkunde</i> , <b>2010</b> , 158, 164-176	0.2	7
104	Disease definition, clinical manifestations, epidemiology and natural history of GERD. <i>Baillieres® Best Practice and Research in Clinical Gastroenterology</i> , <b>2010</b> , 24, 759-64	2.5	53
103	Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 3069-79; quiz 1080	0.7	211
102	Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 1030-8	6.1	349
101	Acid inhibition and infections outside the gastrointestinal tract. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104 Suppl 2, S17-20	0.7	24
100	Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now!. <i>Therapeutic Advances in Gastroenterology</i> , <b>2009</b> , 2, 317-22	4.7	44
99	A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1278-95; quiz 1296	0.7	306
98	Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 756-61	6.9	45
97	The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2009</b> , 21, 394-408	2.2	9
96	Helicobacter pylori. Can Helicobacter pylori infection prevent allergic asthma?. <i>Reviews in Gastroenterological Disorders</i> , <b>2009</b> , 9, E66-7		2
95	Antimicrobial resistance and eradication strategies for Helicobacter pylori. <i>Reviews in Gastroenterological Disorders</i> , <b>2009</b> , 9, E78-83		2
94	Clinical trial design in adult reflux disease: a methodological workshop. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 107-26	6.1	24
93	Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 1304-8	6.1	9
92	Sequential therapy for Helicobacter pylori: time to consider making the switch?. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 300, 1346-7	27.4	22
91	Proton pump inhibitors for dyspepsia. <i>Digestive Diseases</i> , <b>2008</b> , 26, 215-7	3.2	5
90	Endoscopy in GERD: Boondoggle, Diagnostic Test, or Risk Management Tool?. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 276-8	0.7	18
89	Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1906-19	0.7	64

88	An international primary care survey of GERD terminology and guidelines. <i>Digestive Diseases</i> , <b>2008</b> , 26, 231-6	3.2	17
87	Body mass index and gastroesophageal reflux disease: implications of the obesity epidemic. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 2291-2	4	4
86	Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. <i>Clinical Otolaryngology</i> , <b>2008</b> , 33, 114-114	1.8	
85	Approach to gastroesophageal reflux disease in primary care: Putting the Montreal definition into practice. <i>Canadian Family Physician</i> , <b>2008</b> , 54, 701-5	0.9	13
84	Helicobacter pylori treatment: is sequential or quadruple therapy the answer?. <i>Reviews in Gastroenterological Disorders</i> , <b>2008</b> , 8, 77-82		5
83	New pharmacological agents for the treatment of gastroesophageal reflux disease. <i>Reviews in Gastroenterological Disorders</i> , <b>2008</b> , 8, 117-22		2
82	New developments in the treatment of Helicobacter pylori: is sequential therapy the answer?. <i>Reviews in Gastroenterological Disorders</i> , <b>2008</b> , 8, 217-8		1
81	Eradication therapy for Helicobacter pylori. <i>Gastroenterology</i> , <b>2007</b> , 133, 985-1001	13.3	179
80	Review article: the role of surgery in gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 25, 1365-72	6.1	29
79	One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks treatment with esomeprazole: a randomized, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 665-72	6.1	22
78	Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 673-82	6.1	39
77	Unrecognized GERD symptoms are associated with excessive daytime sleepiness in patients undergoing sleep studies. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 2873-6	4	14
76	A BALANCING VIEW: Endoscopy in dyspepsia: a tale of two cities. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 476-7	0.7	2
75	Funding source and conflict of interest disclosures by authors and editors in gastroenterology specialty journals. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 1146-50	0.7	28
74	Can famotidine and omeprazole be combined on a once-daily basis?. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 689-94	2.4	14
73	Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2007</b> , 146, 556-63	8	218
72	Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. <i>Gut</i> , <b>2007</b> , 56, 772-81	19.2	1326
71	Pretreatment endoscopy--pro & contra: is endoscopy needed before treatment in all patients with gastroesophageal reflux disease?. <i>Endoscopy</i> , <b>2006</b> , 38, 276-8	3.4	4

70	Can the clinical history distinguish between organic and functional dyspepsia?. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1566-76	27.4	115
69	<i>Helicobacter pylori</i> treatment: a practical approach. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 497-9	0.7	52
68	Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. <i>Gastroenterology</i> , <b>2006</b> , 131, 390-401; quiz 659-60	13.3	166
67	The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1900-20; quiz 1943	0.7	2533
66	The effect of over-the-counter ranitidine 75 mg on night-time heartburn in patients with erosive oesophagitis on daily proton pump inhibitor maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 649-53	6.1	10
65	Patterns of gastritis and the effect of eradicating <i>Helicobacter pylori</i> on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 55-63	6.1	28
64	The frontiers of reflux disease. <i>Digestive Diseases and Sciences</i> , <b>2006</b> , 51, 1887-95	4	10
63	The prevention of gastropathy and upper abdominal symptoms caused by nonsteroidal anti-inflammatory drugs. <i>Reviews in Gastroenterological Disorders</i> , <b>2006</b> , 6, 221-6		2
62	Guidelines for the management of dyspepsia. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 2324-37	0.7	349
61	Toward a simplified strategy for managing dyspepsia. <i>Postgraduate Medicine</i> , <b>2005</b> , 117, 13-6	3.7	3
60	Review article: how valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22 Suppl 1, 64-9	6.1	66
59	Comprehension and awareness of symptoms in women with dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22, 1147-55	6.1	14
58	<i>Helicobacter pylori</i> eradication: equivalence trials and the optimal duration of therapy. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 1702-3	0.7	12
57	How to test for <i>Helicobacter pylori</i> in 2005. <i>Cleveland Clinic Journal of Medicine</i> , <b>2005</b> , 72 Suppl 2, S8-13; discussion S14-21	2.8	4
56	Increasing compliance with long-term therapy: avoiding complications and adverse events. <i>Reviews in Gastroenterological Disorders</i> , <b>2005</b> , 5 Suppl 2, S12-7		1
55	Antimicrobial resistance incidence and risk factors among <i>Helicobacter pylori</i> -infected persons, United States. <i>Emerging Infectious Diseases</i> , <b>2004</b> , 10, 1088-94	10.2	144
54	Proton pump inhibitors and the time trends for esophageal dilation. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 797-800	0.7	34
53	Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19, 1041-9	6.1	55



52	Seven-day therapy for <i>Helicobacter pylori</i> in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20, 99-107	6.1	119
51	Symptomatic gastro-oesophageal reflux, arousals and sleep quality in patients undergoing polysomnography for possible obstructive sleep apnoea. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20, 1153-9	6.1	30
50	The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. <i>Gastroenterology</i> , <b>2004</b> , 127, 1329-37	13.3	181
49	Long-term strategies: a medico-economic perspective. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 853-6	2.2	2
48	Non-invasive tests for the diagnosis of <i>H. pylori</i> infection. <i>Reviews in Gastroenterological Disorders</i> , <b>2004</b> , 4, 1-6		8
47	The potential dangers of test-and-treat strategies directed at <i>H. pylori</i> . <i>Reviews in Gastroenterological Disorders</i> , <b>2004</b> , 4, 94-5		
46	Pneumatic dilation in achalasia. <i>Endoscopy</i> , <b>2003</b> , 35, 526-30	3.4	12
45	Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. <i>Annals of Internal Medicine</i> , <b>2003</b> , 138, 176-86	8	277
44	Are there geographical and regional differences in <i>Helicobacter pylori</i> eradication?. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2003</b> , 17 Suppl B, 30B-32B		15
43	Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17 Suppl 1, 21-3	6.1	12
42	Review article: test and treat or treat and test in reflux disease?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17 Suppl 2, 57-9	6.1	9
41	Review article: <i>Helicobacter pylori</i> and reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17, 297-305	6.1	80
40	High eradication rates of <i>Helicobacter pylori</i> with a new sequential treatment. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17, 719-26	6.1	161
39	Review article: endoscopic treatments for gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17, 1427-34	6.1	10
38	Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 18, 559-68	6.1	53
37	An overview of the success and failure of surgical therapy: standards against which the outcome of endoscopic therapy is measured. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2003</b> , 13, 69-73, viii	3.3	1
36	Clinical effectiveness of laparoscopic fundoplication in a U.S. community. <i>American Journal of Medicine</i> , <b>2003</b> , 114, 1-5	2.4	137
35	Effect of <i>Helicobacter pylori</i> eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. <i>Gut</i> , <b>2003</b> , 52, 1543-7	19.2	21

34	Gastroesophageal reflux disease and Helicobacter pylori infection. <i>Reviews in Gastroenterological Disorders</i> , <b>2003</b> , 3, 1-7		3
33	Epigastric pain in dyspepsia and reflux disease. <i>Reviews in Gastroenterological Disorders</i> , <b>2003</b> , 3 Suppl 4, S16-21		1
32	Nonulcer dyspepsia. <i>Current Gastroenterology Reports</i> , <b>2002</b> , 4, 455-8	5	3
31	Review article: cost-effectiveness of different GERD management strategies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16 Suppl 4, 79-82	6.1	10
30	Patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 1469-80	6.1	11
29	Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 600-3	0.7	54
28	Esophageal cancer. <i>Current Opinion in Gastroenterology</i> , <b>2002</b> , 18, 486-9	3	2
27	The stool antigen test for detection of Helicobacter pylori after eradication therapy. <i>Annals of Internal Medicine</i> , <b>2002</b> , 136, 280-7	8	88
26	Novel methods of using proton-pump inhibitors. <i>Gastroenterology Clinics of North America</i> , <b>2002</b> , 31, S85-8	4.4	2
25	A prospective trial of a new self-expanding plastic stent for malignant esophageal obstruction. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 1350-4	0.7	54
24	A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 1791-6	0.7	241
23	Dyspepsia, non-ulcer dyspepsia, and Helicobacter pylori. <i>Reviews in Gastroenterological Disorders</i> , <b>2001</b> , 1, 139-46		
22	Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2000</b> , 14, 45-51	6.1	70
21	Helicobacter Pylori and Non-ulcer Dyspepsia. <i>Current Treatment Options in Gastroenterology</i> , <b>2000</b> , 3, 341-345		
20	Is the stool test out of breath?. <i>Digestive and Liver Disease</i> , <b>2000</b> , 32, 291-3	3.3	5
19	The cost-effectiveness of diagnostic testing strategies for. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 1691-1698	0.7	40
18	Human Tissue Responses to Metal Stents. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>1999</b> , 9, 359-365	3.3	36
17	Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. <i>New England Journal of Medicine</i> , <b>1999</b> , 341, 1106-11	59.2	277



16	Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating <i>Helicobacter pylori</i> . <i>American Journal of Gastroenterology</i> , <b>1999</b> , 94, 1197-9	0.7	31
15	Endoscopic Measurement of Lesion Size. <i>Digestive Endoscopy</i> , <b>1999</b> , 11, 193-197	3.7	2
14	Human tissue responses to metal stents. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>1999</b> , 9, 359-65	3.3	14
13	Clarithromycin-resistant <i>Helicobacter pylori</i> in patients with duodenal ulcer in the United States. <i>American Journal of Gastroenterology</i> , <b>1998</b> , 93, 1432-5	0.7	69
12	Cost savings in duodenal ulcer therapy through <i>Helicobacter pylori</i> eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. <i>Archives of Internal Medicine</i> , <b>1998</b> , 158, 852-60		39
11	Treatment of <i>H. pylori</i> infection: the reality. <i>Yale Journal of Biology and Medicine</i> , <b>1998</b> , 71, 119-24	2.4	1
10	A prospective trial of self-expanding metal stents in the palliation of malignant esophageal strictures near the upper esophageal sphincter. <i>Gastrointestinal Endoscopy</i> , <b>1997</b> , 45, 300-3	5.2	51
9	Effect of push enteroscopy on transfusion requirements and quality of life in patients with unexplained gastrointestinal bleeding. <i>American Journal of Gastroenterology</i> , <b>1997</b> , 92, 425-8	0.7	44
8	A prospective trial of self-expanding metal stents in the palliation of malignant esophageal obstruction after failure of primary curative therapy. <i>Gastrointestinal Endoscopy</i> , <b>1996</b> , 44, 283-6	5.2	71
7	Human tissue responses to metal stents implanted in vivo for the palliation of malignant stenoses. <i>Gastrointestinal Endoscopy</i> , <b>1996</b> , 43, 596-602	5.2	96
6	Cost-effectiveness of treatment regimens for the eradication of <i>Helicobacter pylori</i> in duodenal ulcer. <i>American Journal of Gastroenterology</i> , <b>1996</b> , 91, 239-45	0.7	31
5	Metal stents for malignant esophageal obstruction. <i>American Journal of Gastroenterology</i> , <b>1996</b> , 91, 2471-6	0.6	13
4	Measurement of lesions by endoscopy: an overview. <i>Endoscopy</i> , <b>1995</b> , 27, 694-7	3.4	18
3	Short- and long-term outcome of esophageal perforation. <i>Gastrointestinal Endoscopy</i> , <b>1995</b> , 41, 130-4	5.2	50
2	Endoscopic imaging technology. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>1994</b> , 4, 463-73	3.3	
1	A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 1302-7	59.2	623